FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Not Applicable

Completed

Conditions: Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Pure Erythroid Leukemia (M6b)
Chronic Myelomonocytic Leukemia
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Untreated Adult Acute Myeloid Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Monocytic Leukemia (M5b)

Interventions: Drug: pravastatin sodium
Drug: idarubicin
Drug: cytarabine
Other: laboratory biomarker analysis

First Posted Date: 2013-04-15

Last Posted Date: 2017-11-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 24

Registration Number: NCT01831232

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women

Phase 4

Completed

Conditions: HIV

Interventions: Drug: Atripla or Stribild

First Posted Date: 2013-03-21

Last Posted Date: 2022-09-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 225

Registration Number: NCT01815580

Locations: 🇵🇪
Asociación Civil Impacta Salud y Educación, Lima, Peru

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Chronic Myelomonocytic Leukemia
Secondary Myelodysplastic Syndrome
de Novo Myelodysplastic Syndrome
Myelodysplastic Syndrome

Interventions: Drug: Azacitidine (AZC)
Drug: Decitabine
Other: Quality-of-Life Assessment

First Posted Date: 2013-03-18

Last Posted Date: 2024-02-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 50

Registration Number: NCT01812252

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Kaiser Permanente Washington, Seattle, Washington, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 1 locations

Randomized Trial of Web-Delivered Acceptance Therapy for Smoking Cessation (WebQuit)

Not Applicable

Completed

Conditions: Smoking

Interventions: Behavioral: ACT
Behavioral: CBT

First Posted Date: 2013-03-18

Last Posted Date: 2020-07-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2637

Registration Number: NCT01812278

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Innovative Smartphone Application of a New Behavioral Method to Quit Smoking: Pilot Trial (Smart Quit)

Not Applicable

Completed

Conditions: Smoking

Interventions: Behavioral: CBT
Behavioral: ACT

First Posted Date: 2013-03-15

Last Posted Date: 2015-03-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 196

Registration Number: NCT01812070

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
Metastatic Melanoma
Stage III Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7

Interventions: Biological: Aldesleukin
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Biological: Therapeutic Tumor Infiltrating Lymphocytes

First Posted Date: 2013-03-08

Last Posted Date: 2022-11-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 11

Registration Number: NCT01807182

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia

Not Applicable

Completed

Conditions: Myelodysplastic Syndrome
Acute Myeloid Leukemia
Acute Biphenotypic Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions: Other: Laboratory Biomarker Analysis
Drug: Liposomal Cytarabine-Daunorubicin CPX-351

First Posted Date: 2013-03-05

Last Posted Date: 2018-05-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 48

Registration Number: NCT01804101

Locations: 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

Not Applicable

Withdrawn

Conditions: HIV-associated Hodgkin Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Mycosis Fungoides/Sezary Syndrome
Splenic Marginal Zone Lymphoma
Stage IV AIDS-related Lymphoma
AIDS-related Diffuse Small Cleaved Cell Lymphoma
AIDS-related Peripheral/Systemic Lymphoma
Hepatosplenic T-cell Lymphoma
Peripheral T-cell Lymphoma

Interventions: Drug: carmustine
Drug: cytarabine
Drug: melphalan
Drug: etoposide
Drug: O6-benzylguanine
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2013-01-17

Last Posted Date: 2015-05-07

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT01769911

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma

Phase 1

Terminated

Conditions: Recurrent Merkel Cell Carcinoma
Stage IV Merkel Cell Carcinoma

Interventions: Biological: Aldesleukin
Other: Laboratory Biomarker Analysis
Biological: MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells
Radiation: Radiation Therapy
Biological: Recombinant Interferon Beta

First Posted Date: 2013-01-01

Last Posted Date: 2017-04-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 4

Registration Number: NCT01758458

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Supportive Care for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant

Not Applicable

Completed

Conditions: Hematopoietic/Lymphoid Cancer

Interventions: Other: palliative care
Other: questionnaire administration
Procedure: quality-of-life assessment

First Posted Date: 2013-01-01

Last Posted Date: 2016-03-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01758484

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy